Stocks Soar On Fauci-Touted Remdesivir Study Despite Marginal Survival Benefit, Snubs Lancet Findings

Corona Virus Treatment

"Update (13:15ET): The NIAD has released a statement on the Gilead remdesivir study. The statement repeated some of the numbers Dr. Fauci shared at the press conference - that patients who took remdesivir saw 31% faster time to recovery than the placebo group, while mortality rates "improved" to 8% from 11.6% an improvement of 3.6 percentage points, which Dr. Fauci acknowledged wasn't "statistically significant.""


See the first comment for an unencouraging update.

Read Our Latest News

Showing 1 reaction

Please check your e-mail for a link to activate your account.

This is an independent expenditure prepared and paid for by RIGHT NOW MINNESOTA, 8014 Olson Memorial HWY 55 #543 Golden Valley, MN 55427. It is not coordinated with or approved by any candidate nor is any candidate responsible for it.